67 results about "Traumatic Stress Disorders" patented technology

A method, computer-readable media, and system associated with psychiatric and physiologic monitoring of a patient having PTSD or anxiety-related mental health conditions are provided. For example, data associated with a survey or questionnaire that was provided to a patient is received. A score may be determined from the data associated with the survey or questionnaire. A time-series is formed using heart-rate measurements detected by a sensor. Fractal properties, such as a Hurst exponent, may be calculated for the time-series. The score may be contextually matched to a set of reference scores. Further, the contextual matching may be used to determine a range of normative HRV values for determining whether a value associated with the patient is within the range. If the value associated with the patient is not within the range, a notification may be provided.

This invention discloses the application of ethinylestradiol and drospirenone in the preparation of drugs for treating post-traumatic stress disorder (PTSD). Ethinylestradiol, as an estrogen receptor agonist, regulates the hypothalamic-pituitary-gonadal axis and is used to treat female hypogonadism, menopausal syndrome, and advanced breast cancer, often in combination with progestins as oral contraceptives. The use of drospirenone and ethinylestradiol tablets (II) after induced abortion can shorten vaginal bleeding time, promote endometrial repair, and reduce the incidence of postoperative complications and repeat miscarriages. This invention has found that ethinylestradiol and drospirenone can reverse the abnormal decrease in hormones and neurosteroids caused by PTSD after spontaneous abortion, particularly the abnormal decrease in serotonin and tetrahydroprogesterone.

Compounds having formula (I), or pharmaceutically acceptable salts, solvates, or prodrugs thereof are provided. The compounds, or pharmaceutically acceptable salts, solvates, or prodrugs thereof, may be used for the treatment or prevention of disorders for which ASIC inhibitors are indicated. The use of compound C having formula (I'), or pharmaceutically acceptable salts, solvates, or prodrugs thereof, for the preparation of pharmaceutical compositions for the treatment or prevention of disorders for which ASIC inhibitors are indicated is also provided. In some embodiments, pharmaceutical compositions prepared using the compound of formula (I), or pharmaceutically acceptable salts, solvates, or prodrugs thereof, or compound C, are for the treatment or prevention of pain, arthritis, stroke, epileptic disorders, anxiety, post-traumatic stress disorder (PTSD), depression, multiple sclerosis, Alzheimer's disease, gastroesophageal reflux disease, cancer, migraine, cough, or acute lung injury. [Formula 1] JPEG2026511139000245.jpg21170

The present invention relates to a compound of formula (I) as inhibitors of calcium calmodulin dependent protein kinase 2 (CAMK2) for the treatment of for the treatment of heart failure, fibrosis, cardiomyopathies, atrial fibrillation, catecholaminergic polymeric ventricular tachycardia, heart block, cardiac arrhythmias, contraception, anxiety, post-traumatic stress disorder, hypertension, tachycardia, diabetes, allergy, and asthma.

The present invention relates to a compound of formula (I) as inhibitors of calcium calmodulin dependent protein kinase 2 (CAMK2) for the treatment of for the treatment of heart failure, fibrosis, cardiomyopathies, atrial fibrillation, catecholaminergic polymeric ventricular tachycardia, heart block, cardiac arrhythmias, contraception, anxiety, post-traumatic stress disorder, hypertension, tachycardia, diabetes, allergy, and asthma.

The application provides a traditional Chinese medicine composition for preventing post-traumatic stress disorder and a preparation method thereof. The traditional Chinese medicine composition for preventing post-traumatic stress disorder comprises the following raw materials in parts by weight: 10-20 parts of ginseng and 10-20 parts of rhizoma polygonati, and in addition, 15-25 parts of mulberry, 15-25 parts of hawthorn and 5-15 parts of raphanus sativus. The traditional Chinese medicine composition is reasonably matched, has the effects of nourishing heart and soothing nerves, benefiting qi and nourishing blood, invigorating spleen and benefiting stomach and can well play a role in preventing post-traumatic stress disorder.

Methods and systems for improving medical conditions by delivering a focused ultrasound signal to target sites of the brain. The focused ultrasound signal can have a mechanical index of between about 1.0 to about 8.0 and / or an acoustic pressure of between about 1.0 MPa to about 3.0 MPa. The medical condition can comprise addiction (including binge eating), anxiety disorders and anxiety associated disorders, tinnitus, neurodegenerative disorders, neuropsychiatric disorders, cognitive disorders, neurodevelopmental disorders, post-traumatic stress disorder, stroke recovery, and combinations thereof.

Cannabinoid analogs may exhibit anti-inflammatory properties such as by inhibition of cannabinoid type 2 (CB2) receptors. Pharmaceutical compositions comprising the cannabinoid analogs may be used to treat various diseases and conditions in mammals, including pain, anxiety, a sleep disorder, addiction, epilepsy, depression, post-traumatic stress disorder or Alzheimer's disease. In some examples, the pharmaceutical compositions may be administered for treating a cognitive disorder or for improving cognition.

This application discloses the use of ritonavir or its derivatives in the preparation of medicaments for treating mental disorders. This application also discloses the discovery of mice (AtLAS) with difficulty in extinction of fear memories. ‑ / ‑ Intraperitoneal injection of ritonavir significantly restored the rigidity rate in model mice. Further immunoblotting and co-precipitation confirmed that ritonavir could significantly block the binding of Syn2a and Syngr-3, and promote the formation of VAMP2, Syntaxin, and SNAP25 trimers, thereby promoting the normal release of presynaptic membrane vesicles in neurons and restoring the rigidity rate in mice with refractory rigidity, thus achieving the treatment of mental disorders such as post-traumatic stress disorder.

Provided herein are methods and compositions for treating neurological diseases (e.g., neurodegenerative disorders (e.g., Alzheimer's disease, Parkinson's disease, dementia, a tauopathy, chronic traumatic encephalopathy (CTE), traumatic brain injury (TBI), mild cognitive impairment); psychiatric disorders (e.g., bipolar disorder, schizophrenia, depression, anxiety, post-traumatic stress disorder, obsessive compulsive disorder); inflammation in the central nervous system) using lithium salts, activators that increase the expression or activity of the RE1 silencing transcription factor (REST), or a combination thereof, or in combination with an additional agent.

This invention belongs to the field of biomedical technology, and specifically relates to a nutrient composition for the prevention and / or treatment of post-traumatic stress disorder (PTSD). This invention utilizes metabolomics technology to screen and identify metabolite changes occurring during the pathophysiological process of PTSD, and then designs a nutrient composition comprising five components: α-ketoglutarate, thiamine hydrochloride, L-serine, L-tryptophan, and L-tyrosine. Combined supplementation of these five nutrient components effectively improves anxiety-like behavior and promotes the extinction of fear memories in PTSD model mice. Furthermore, the nutrient composition of this invention exhibits extremely high safety, with side effects far lower than traditional chemically synthesized drugs, and is expected to improve long-term patient adherence.

This invention relates to the use of (i) a 5-HT2A agonist (including 5-HT2A agonists that bind to a BDNF receptor, e.g., a 5-HT2A agonist that binds to the TrkB receptor or p75NTR), (ii) a therapeutic agent that promotes neuroplasticity by stimulation of the 5-HT2A receptor, (iii) a therapeutic agent that releases BDNF by stimulation of the 5-HT2A receptor (including those therapeutic agents that stimulate the 5-HT2A receptor and bind to a TrkB receptor or p75NTR), (iv) an AMPA positive allosteric modulator, (v) a therapeutic agent that promotes neuroplasticity by stimulation of the AMPA receptor, (vi) a therapeutic agent that releases BDNF by stimulation of the AMPA receptor, or (vii) an NMDA receptor positive allosteric modulator (such as a stinel compound) in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), bipolar disorder, post-traumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms) in select patients who, for instance, have objectively determined cognitive impairment or poor cognition (such as objectively determined impaired learning and / or memory) and / or certain EEG characteristics.

Compounds having formula (I), or pharmaceutically acceptable salts, solvates, or prodrugs thereof are provided. Pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable salt, solvate, or prodrug thereof, and a pharmaceutically acceptable carrier, diluent, or excipient are also provided. Compounds, or pharmaceutically acceptable salts, solvates, or prodrugs thereof, or pharmaceutical compositions comprising them, may be used for the treatment or prevention of disorders for which ASIC inhibitors are indicated. In some embodiments, compounds, or pharmaceutically acceptable salts, solvates, or prodrugs thereof, or pharmaceutical compositions comprising them, may be used for the treatment or prevention of pain, arthritis, stroke, epileptic disorders, anxiety, post-traumatic stress disorder (PTSD), depression, multiple sclerosis, Alzheimer's disease, gastroesophageal reflux disease, cancer, migraine, cough, or acute lung injury. [Formula 1] JPEG2026511124000359.jpg20170

Methods and compositions are disclosed for rapidly relieving symptoms in subjects with depressive, stressor and substance abuse conditions, e.g., major depression, treatment-resistant depression, post-partum depression, bipolar depression, post-traumatic stress disorder, substance use disorders, negative and cognitive symptoms of schizophrenia, as well as for slowing progression of mild cognitive impairment and dementia, using an intermittent dosing regimen of memantine or amantadine or a structural analogue or pharmaceutically acceptable salt of memantine or amantadine (optionally no more frequently than every 2 days) at a dose sufficient to activate Set A brain structures, in combination with a second drug at a dose which activates Set B brain structures but which does not appreciably evoke brain activity linked to hallucinogenic and other psychotomimetic perceptions. In some instances the second drug is either 1) a low dose psilocybin or low dose of other psychedelic and stimulant molecules capable of activating Set B of brain structures which is administered at a dose low enough such that it does not appreciably evoke brain activity linked to hallucinogenic and other psychotomimetic perceptions, or is 2) mianserin (S isomer, R isomer, or a racemate comprising both isomers or structural analog or pharmaceutically acceptable salt thereof) or another standard of care antidepressant capable of activating Set B brain structures, or 3) lumateperone or another antipsychotic capable of activating Set B brain structures.

The application discloses application of methylphenidate in preparation of a post-traumatic stress disorder (PTSD) psychotherapy enhancer. The methylphenidate is used in the introduction period of PTSD psychotherapy, and can improve the treatment effect of core symptoms of PTSD, including intrusive symptoms, avoidance symptoms, high vigilance symptoms, negative thinking and emotion. The application uses single methylphenidate to disturb patients into an unstable state, adjusts a time window for reconsolidation of trauma memory, and strengthens the decline of trauma memory and the update of healing memory in the time window. Furthermore, compared with daily medication, single medication has clinical significance of reducing the psychological burden and economic burden of patients on drug use. Therefore, the application uses single methylphenidate in the introduction period of PTSD psychotherapy.

This invention provides an application of the combined use of rhizoma sarcodactylis and ginsenosides in the prevention and / or treatment of neuropsychiatric disorders, relating to the field of biomedical technology. The combined use of rhizoma sarcodactylis and ginsenosides demonstrates significant effects in improving symptoms of post-traumatic stress disorder (PTSD) and depression, exhibiting a synergistic effect. It effectively alleviates invasive symptoms caused by post-traumatic stress events; reduces fear-avoidance of trauma-related stimuli in mice; effectively improves hypervigilance states such as arousal and sleep disturbances; significantly reduces anxiety levels in stressed mice; reverses stress-induced anhedonia; not only fades traumatic memories but also protects and improves normal neutral memory function; and for depression, it effectively reduces anxiety-like and depression-like behaviors in depressed model mice, overcoming the memory generalization problem that may arise from traditional treatments.

Subject matter of the present invention is iron supplementation for treatment and / or prophylaxis of an affective disorder and / or post-traumatic stress disorder (PTSD) and / or serotonin-dependent diseases in a human patient in need thereof. Subject matter of the present invention is in particular iron supplementation for treatment and / or prophylaxis of depression, in particular of a major depressive disorder (MDD) in a human patient in need thereof.

The present invention relates to a compound of formula (I) as inhibitors of calcium calmodulin dependent protein kinase 2 (CAMK2) for the treatment of for the treatment of heart failure, fibrosis, cardiomyopathies, atrial fibrillation, catecholaminergic polymeric ventricular tachycardia, heart block, cardiac arrhythmias, contraception, anxiety, post-traumatic stress disorder, hypertension, tachycardia, diabetes, allergy, and asthma.

A method, computer-readable media, and system associated with psychiatric and physiologic monitoring of a patient having PTSD or anxiety-related mental health conditions are provided. For example, data associated with a survey or questionnaire that was provided to a patient is received. A score may be determined from the data associated with the survey or questionnaire. A time-series is formed using heart-rate measurements detected by a sensor. Fractal properties, such as a Hurst exponent, may be calculated for the time-series. The score may be contextually matched to a set of reference scores. Further, the contextual matching may be used to determine a range of normative HRV values for determining whether a value associated with the patient is within the range. If the value associated with the patient is not within the range, a notification may be provided.

To provide a reduction in the side effects of NMDA antagonists. [Solution] This disclosure relates to compositions comprising racemiketamine or a pharmaceutically acceptable salt thereof for use in the treatment of mental disorders such as suicidal tendencies, suicidal ideation, major depressive disorder, treatment-resistant depression, and post-traumatic stress disorder. Some embodiments provide a method for treating suicidal tendencies in subjects requiring treatment of suicidal tendencies, comprising intranasal administration of a therapeutically effective amount of racemiketamine or a pharmaceutically acceptable salt thereof to the subject.

This invention relates to the use of mGluR5 positive allosteric modulators in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder, bipolar disorder, post-traumatic stress disorder, substance use disorder, depression-related aspects of schizophrenia (e.g. negative symptoms and cognitive impairment associated with schizophrenia), obsessive compulsive disorder, an eating disorder, autism spectrum disorder, chemotherapy-related cognitive dysfunction, Parkinson's disease, multiple sclerosis, clinical high risk for psychosis, and attenuated psychosis syndrome in select patients who, for instance, have objectively determined cognitive impairment or poor cognition (such as objectively determined impaired learning and / or memory) and / or certain EEG characteristics.

The invention discloses a nicardipine delivery system and application of the nicardipine delivery system in resisting post-traumatic stress disorder. According to the present invention, the functional modification is performed on the PLGA-PEG to develop the brain enrichment type PLGA-PEG-MANNOse molecule, the nicardipine is subjected to nanometer modification, the blood brain barrier permeability is enhanced, and the fear memory disorder of the post-traumatic stress disorder model animal can be effectively relieved; research finds that when PPM-N is used for treating mice related to electric shock complicated post-traumatic stress disorder, indexes of multiple experimental results are equivalent to serotonin reuptake inhibitor medicine sertraline. Related experiments show that PPM-N has the effect of treating and / or relieving post-traumatic stress disorder and has a good clinical application prospect.

The present invention relates to a compound of formula (I) as inhibitors of calcium calmodulin dependent protein kinase 2 (CAMK2) for the treatment of for the treatment of heart failure, fibrosis, cardiomyopathies, atrial fibrillation, catecholaminergic polymeric ventricular tachycardia, heart block, cardiac arrhythmias, contraception, anxiety, post-traumatic stress disorder, hypertension, tachycardia, diabetes, allergy, and asthma.

This invention belongs to the field of pharmaceutical technology, specifically relating to the application of N-methyltyramine in the preparation of drugs for improving anger and irritability. The CAS number of the N-methyltyramine (NMT) is 370-98-9. Experimental results show that NMT can directly target and positively regulate the γ-aminobutyric acid type A receptor (GABA). a NMT activates the downstream AC5-cAMP-PKA signaling pathway, thereby improving abnormal emotional states such as anger and depression. Through network pharmacology, molecular docking, micro-thermophoresis experiments, animal behavioral experiments, and cell experiments, NMT significantly improves the behavior of model animals. Therefore, this invention reveals for the first time that NMT improves abnormal emotional states such as anger and depression through GABA. a The mechanism by which R-related signaling pathways play a role in mood regulation can be used to prepare drugs for treating mood disorders such as anxiety, depression, and post-traumatic stress disorder, and has good application prospects.

The present disclosure relates to compositions comprising racemic ketamine or a pharmaceutically acceptable salt thereof for use in the treatment of psychiatric disorders such as suicide propensity, suicide idea, major depression, anti-therapeutic depression, and post-traumatic stress disorders.

The invention provides a biomarker for diagnosing post-traumatic stress disorder and application of the biomarker, and belongs to the technical field of artificial intelligence medical treatment. The biomarker comprises at least one of matrix metallopeptidase 14, alpha1-antitrypsin, a macrophage migration inhibition factor, a tryptophan-tRNA ligase and a cell growth factor activator. The marker has high sensitivity and specificity in diagnosis of the post-traumatic stress disorder, can effectively diagnose the post-traumatic stress disorder in an early stage, provides a treatment target for subsequent treatment of the post-traumatic stress disorder, and has good clinical use and popularization and application values.

This disclosure relates to heterocyclic compounds of Formula (I) as well as the preparation and use thereof. As contemplated herein, heterocyclic compounds of Formula (I) can be any one of a carbohydrate conjugate and an amino acid conjugate. The heterocyclic compounds of Formula (I) may be used for the treatment of neuropsychiatric, and neurodegenerative, neuroinflammatory and pain disorders including depression, as well as tobacco, opiate, and cocaine addiction, alcoholism, post-traumatic stress disorder (PTSD), and pain syndromes including cluster headaches and chemotherapy induced peripheral neuropathy.

The invention relates to an inula flower composition which is prepared by the following steps: (1) adding water into an inula flower extract to be purified according to the weight-volume ratio of the inula flower extract to the water being 1: (10-20), and performing ultrasonic dispersion to prepare a suspension; (2) adding petroleum ether into the prepared suspension according to the volume ratio of the petroleum ether to the suspension being (1-3): 1, performing ultrasonic extraction, removing a petroleum ether layer, and retaining a water layer; (3) repeating the ultrasonic extraction operation in the step (2) for 1-3 times, adding water to dilute a water layer, performing ultrasonic dispersion, filtering and collecting filtrate; (4) loading the filtrate on macroporous resin, carrying out static adsorption for 10-18 hours, collecting the effluent, and circularly loading the sample; and (5) sequentially eluting with deionized water, a 10% ethanol solution, a 20% ethanol solution, a 30% ethanol solution and a 50% ethanol solution, collecting the eluent eluted with the 30% ethanol solution and the eluent eluted with the 50% ethanol solution, concentrating, and drying to obtain the traditional Chinese medicine composition. The inula flower composition disclosed by the invention has excellent activity of resisting post-traumatic stress disorder (PTSD) and the like.

The present specification discloses methods for treating a PTSD. The methods comprise extramuscularly administering a Botulinum toxin to an individual in one or more areas of a fronto-fascial layer located in a frontal head region, one or more areas of a temporoparietal-fascial layer located in a temporal head region, and one or more areas of an occipito-fascial layer located in an occipital head region. The methods further comprise extramuscularly administering a Botulinum toxin to one or more nerve exit points and / or one or more subcutaneous locations in the head and neck and / or one or more sites of an epicranial aponeurosis. The methods further comprise intramuscularly administering a Botulinum toxin to one or more locations within the left and right Splenius Capitis muscle, the left and right Masseter muscles, the left and right Trapezius muscles, or any combination thereof.

The invention discloses a laboratory mouse model construction method for post-traumatic stress disorder research, which comprises the following steps: step S01, putting a laboratory mouse into a conditional fear test box, and adapting to the environment of the conditional fear test box; s02, applying conditional stimulation to the laboratory mouse for a first preset time, wherein the conditional stimulation comprises sound signal stimulation or constraint stress; before or when the conditional stimulation is finished, electric shock is applied to the laboratory mouse for a second preset time, and the current of the electric shock is 1.2-1.6 mA; and S03, repeating the step S02 for preset times, and obtaining the laboratory mouse model for post-traumatic stress disorder research by taking the time interval between two adjacent repetitions as third preset time.